Title :

Systemic pulmonary events associated with myelodysplastic syndromes: a retrospective multicentre study

Author(s) :

Scanvion, Quentin [Auteur]
Université Lille Nord (France)
Pascal, Laurent [Auteur]
Hôpital Saint Vincent de Paul de Lille
Sy, Thierno [Auteur]
Stervinou-Wemeau, Lidwine [Auteur]
Service de Pneumologie et Immuno-Allergologie [CHU LIlle]
Lejeune, Anne-Laure [Auteur]
Centre Hospitalier Régional Universitaire [Lille] [CHRU Lille]
Deken, Valerie [Auteur]
METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
Hachulla, Eric [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Quesnel, Bruno [Auteur]
Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290
Mekinian, Arsene [Auteur]
CHU Saint-Antoine [AP-HP]
Launay, David [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Terriou, Louis [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
Laurent, Pascal [Auteur]

Journal title :

Journal of clinical medicine

Abbreviated title :

J Clin Med

Volume number :

10

Pages :

1162

Publisher :

MDPI

Publication date :

2021-03-10

ISSN :

2077-0383

Keyword(s) :

iatrogenic effects
pulmonary hypertension
pleuritic effusion
pneumonia
interstitial lung disease
pulmonary alveolar proteinosis

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Although pulmonary events are considered to be frequently associated with malignant haemopathies, they have been sparsely studied in the specific context of myelodysplastic syndromes (MDS). We aimed to describe their ...
Show more >Although pulmonary events are considered to be frequently associated with malignant haemopathies, they have been sparsely studied in the specific context of myelodysplastic syndromes (MDS). We aimed to describe their different types, their relative proportions and their relative effects on overall survival (OS). We conducted a multicentre retrospective cohort study. Patients with MDS (diagnosed according to the 2016 WHO classification) and pulmonary events were included. The inclusion period was 1 January 2007 to 31 December 2017 and patients were monitored until August 2019. Fifty-five hospitalized patients were included in the analysis. They had 113 separate pulmonary events. Thirteen patients (23.6%) had a systemic autoimmune disease associated with MDS. Median age at diagnosis of MDS was 77 years. Median time to onset of pulmonary events was 13 months. Pulmonary events comprised: 70 infectious diseases (62%); 27 interstitial lung diseases (23.9%), including 13 non-specific interstitial pneumonias and seven secondary organizing pneumonias or respiratory bronchiolitis-interstitial lung diseases; 10 pleural effusions (8.8%), including four cases of chronic organizing pleuritis with exudative effusion; and six pulmonary hypertensions (5.3%). The median OS of the cohort was 29 months after MDS diagnosis but OS was only 10 months after a pulmonary event. The OS was similar to that of the general myelodysplastic population. However, the occurrence of a pulmonary event appeared to be either an accelerating factor of death or an indicator for the worsening of the underlying MDS in our study. More than a third of pulmonary events were non-infectious and could be systemic manifestations of MDS.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

CHU Lille
CNRS
Inserm
Université de Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286
• METRICS : Evaluation des technologies de santé et des pratiques médicales - ULR 2694
• Miniaturisation pour la Synthèse, l'Analyse et la Protéomique (MSAP) - USR 3290

Submission date :

2021-07-06T12:50:54Z
2022-11-16T08:00:26Z